Clinical trials
Psoriasis clinical trials
A skin condition that causes a rash with itchy, scaly patches. We’re tracking 164 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07410793RecruitingPhase 2
Acupuncture plus herbal cream vs standard cream for plaque psoriasis
This trial tests if adding a Chinese herbal cream to acupuncture works as well as adding a standard psoriasis cream (calcipotriol) to acupuncture. It's for people with mild to moderate plaque psoriasis and may offer a natural treatment option.
Muang, ChiangraiAges 18–65 - NCT06912165RecruitingPhase 2
WD-890 for moderate to severe plaque psoriasis
This study tests an investigational drug called WD-890 for people with moderate-to-severe plaque psoriasis that hasn't responded well enough to other treatments. It may help reduce skin patches, scaling, and itching.
Nanjing, JiangsuAges 18–70 - NCT07663331RecruitingPhase 4
Adalimumab for adults with non-infectious uveitis
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05858645RecruitingPhase 4
Deucravacitinib to correct immune signals in psoriasis
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
San Francisco, CaliforniaAges 18–75 - NCT06888193RecruitingPhase 1
Bimekizumab in breast milk of mothers being treated
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Santa Monica, CaliforniaAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT04170244Recruiting
Skin microbiome study in atopic dermatitis and psoriasis
This study looks at the skin’s germs (“microbiome”) in people with atopic dermatitis (eczema) or psoriasis. It may help researchers better understand what’s going on on the skin and how that might relate to disease severity.
Rochester, New YorkAges 13 years+ - NCT04191395Recruiting
Study of treatments for long-term inflammatory diseases
This study looks at how chronic inflammatory illnesses progress over time and how treatments affect symptoms and disease markers. You may be invited if you’re receiving care for certain bowel, joint, or skin inflammatory conditions at the hospital.
BesançonAges 18 years+ - NCT04751396Recruiting
Melanoma education for people with autoimmune conditions
This trial tests an educational tool to help people with melanoma and pre-existing autoimmune disease understand immune checkpoint inhibitor treatment. It aims to support you and your care team with information that can help you make decisions and feel more prepared.
Houston, TexasAges 18 years+ - NCT04806620Recruiting
Online app study for brain inflammation lifestyle data
This study uses a digital platform (app/website) to collect lifestyle and symptom information to better understand brain inflammation. You may qualify if you have certain conditions like Long COVID, migraines, autoimmune disease, inflammatory gut issues, mood disorders, or if you are a healthy comparison person.
Delafield, WisconsinAges 2 years+ - NCT04846959Recruiting
Pregnancy outcomes study for people exposed to risankizumab
This study looks at pregnancy outcomes in people who took risankizumab during pregnancy (or shortly before getting pregnant). It compares them with pregnancies exposed to similar biologic medicines, to better understand risks and what to expect.
Morrisville, North CarolinaAges Any age - NCT04864886Recruiting
Study how immune-related conditions affect metabolism
This study collects blood and other samples to see how the immune system changes “metabolism” (how your body uses energy) in people with immune-related conditions. Your samples may also be stored for future research and could help researchers better understand immune health.
Bethesda, MarylandAges 18–75 - NCT05004727RecruitingPhase 4
Study for a psoriasis medicine in adults
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Boston, MassachusettsAges 18 years+ - NCT05285839RecruitingPhase 4
Dupixent plus UVB light for moderate to severe eczema
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
East Windsor, New JerseyAges 18 years+ - NCT05500794Recruiting
Meditation for itch from psoriasis or eczema
This trial studies whether meditation can reduce itching and improve quality of life in adults with plaque psoriasis or atopic dermatitis (eczema). It may help by calming the mind and reducing discomfort related to inflammatory skin disease.
ParisAges 3 weeks+ - NCT05858528Recruiting
Study following adults with skin psoriasis over time
This observational study is looking at adults with skin psoriasis and collecting real-world information about their condition and experiences. It may help researchers better understand psoriasis and how it affects people, without giving a new treatment.
Oxford, OxfordshireAges 18 years+ - NCT05883371Recruiting
IMPACT autoimmune study registry for people on biologic medicines
This study is a registry that collects health information from adults with certain autoimmune conditions who are currently using (or have been recommended) biologic or DMARD medicines. It may help researchers better understand these diseases and how treatments affect people over time.
Columbus, OhioAges 18–70 - NCT05928169Recruiting
Tracking how inflammatory skin conditions change over time
This study looks at what affects the “path” (trajectory) of long-lasting inflammatory skin conditions. It may help researchers understand why symptoms change and how treatments or factors influence those changes.
KielAges birth–80 years - NCT05994976Recruiting
Collecting skin samples from people with skin conditions
This study collects skin samples (like small biopsies or swabs) from people with certain skin conditions and from healthy volunteers. The samples help researchers learn more about these conditions and may lead to better treatments.
Montreal, QuebecAges 18 years+ - NCT06376474RecruitingPhase 1
How Hemay005 is processed in people with liver damage
This study looks at how a new drug called Hemay005 behaves in people with mild or moderate long-term liver damage. It helps doctors understand if the drug needs a different dose for people with liver problems.
Wuhan, HubeiAges 18–70 - NCT06599411Recruiting
Skin biomarkers for inflammatory disease treatment
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
ParisAges 18 years+ - NCT06846710RecruitingPhase 1
Testing HS-20118 in healthy adults and psoriasis patients
This study tests a new medicine called HS-20118 in two parts: one in healthy adults to see how the body handles a single dose, and another in people with chronic plaque psoriasis to see how it works over multiple doses. It helps find a safe dose and shows whether it might reduce psoriasis symptoms.
Anaheim, CaliforniaAges 18–65 - NCT06857942RecruitingPhase 4
Tirzepatide added to ixekizumab for psoriasis and weight issues
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
Phoenix, ArizonaAges 18 years+ - NCT06989216Recruiting
Skin imaging study for adults
This trial uses advanced imaging to take detailed pictures of your skin. It may help doctors better understand and diagnose skin conditions.
StockholmAges 18 years+
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psoriasis?
- Yes. Clin2 currently lists 164 recruiting psoriasis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psoriasis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psoriasis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.